Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424225 · ClinicalTrials.gov registry record · Phase 1
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
A Phase 1 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04424225 is a Phase 1 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 10 participants.
The verdict
NCT04424225, a Phase 1 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The prospective pilot study will address the critical need for more precise characterizations of the acute visual effects of the drug psilocybin by measuring the impact of acute psilocybin intoxication on a perceptual task known as visual surround suppression, compared to an active placebo control.
Interventions
- DRUG Niacin
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424225
The ClinicalTrials.gov registry entry for NCT04424225 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Niacin is the first listed.
NCT04424225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04424225 about?
NCT04424225 is a clinical study titled "Visual Surround Suppression and Perceptual Expectation Under Psilocybin". The prospective pilot study will address the critical need for more precise characterizations of the acute visual effects of the drug psilocybin by measuring the impact of acute psilocybin intoxication on a perceptual task known as visual surround suppression, compared to an active placebo control.
What is the current status of trial NCT04424225?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-08-30. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT04424225?
The interventions under investigation include: Niacin (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04424225?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.